Patents by Inventor Alan Arnold ADEREM

Alan Arnold ADEREM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for prospective determination of risk for development of active tuberculosis
    Patent number: 11220717
    Abstract: This invention relates to a prognostic method for determining the risk of an asymptomatic human subject with latent tuberculosis (TB) infection or apparent latent TB infection and/or after suspected exposure to TB progressing to active tuberculosis disease comprising the steps of quantifying and computationally analysing relative abundances of a collection of pairs of gene products (“TB biomarkers”) derived from a sample obtained from the subject. The invention further relates to a collection of TB biomarkers that generates a transcriptomic signature of risk for prediction of the likelihood of an asymptomatic human subject with latent TB infection and/or after suspected exposure to TB progressing to active tuberculosis disease. Furthermore, a kit comprising gene-specific primers or oligonucleotide probes for the detection of pairs of TB biomarkers that generates a prognostic signature of risk for use with the method of the invention is described.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: January 11, 2022
    Assignees: Seattle Children's Hospital, University of Cape Town
    Inventors: Adam Garth Penn-Nicholson, Thomas Jens Scriba, Alan Arnold Aderem, Daniel Edward Zak, Ethan Greene Thompson, Willem Albert Hanekom
  • BIOMARKERS FOR PROSPECTIVE DETERMINATION OF RISK FOR DEVELOPMENT OF ACTIVE TUBERCULOSIS
    Publication number: 20190249228
    Abstract: This invention relates to a prognostic method for determining the risk of an asymptomatic human subject with latent tuberculosis (TB) infection or apparent latent TB infection and/or after suspected exposure to TB progressing to active tuberculosis disease comprising the steps of quantifying and computationally analysing relative abundances of a collection of pairs of gene products (“TB biomarkers”) derived from a sample obtained from the subject. The invention further relates to a collection of TB biomarkers that generates a transcriptomic signature of risk for prediction of the likelihood of an asymptomatic human subject with latent TB infection and/or after suspected exposure to TB progressing to active tuberculosis disease. Furthermore, a kit comprising gene-specific primers or oligonucleotide probes for the detection of pairs of TB biomarkers that generates a prognostic signature of risk for use with the method of the invention is described.
    Type: Application
    Filed: November 9, 2016
    Publication date: August 15, 2019
    Applicants: UNIVERSITY OF CAPE TOWN, CENTER FOR INFECTIOUS DISEASE RESEARCH
    Inventors: Adam Garth PENN-NICHOLSON, Thomas Jens SCRIBA, Alan Arnold ADEREM, Daniel Edward ZAK, Ethan Greene THOMPSON, Willem Albert HANEKOM